Bavarian Nordic Aktie

29,86 EUR -0,21 EUR -0,70 %

08:03:50

FSE

30,66 EUR +0,02 EUR +0,07 %

30.09.2025

GVIE

Bavarian Nordic jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.2,40 Mrd. EUR

KGV14,97Div. Rendite0,00%

WKN917165

ISINDK0015998017

SymbolBVNKF

Bavarian Nordic Aktien News

Sortieren:Datum Meistgelesen

12.06.25GlobeNewswireBavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children

09.05.25GlobeNewswireReport of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

09.05.25GlobeNewswireBavarian Nordic Announces Interim Results for the First Three Months of 2025

WerbungBavarian Nordic-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

06.05.25GlobeNewswireBavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines

02.05.25GlobeNewswireBavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom

16.04.25GlobeNewswireBavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)

09.04.25GlobeNewswireResolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

31.03.25GlobeNewswireBavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine

12.03.25GlobeNewswireBavarian Nordic A/S – Notice Convening Annual General Meeting

07.03.25GlobeNewswireBavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

05.03.25GlobeNewswireReport of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

05.03.25GlobeNewswireBavarian Nordic Publishes Annual Report 2024

28.02.25GlobeNewswireBavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

25.02.25GlobeNewswireBavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

14.02.25GlobeNewswireBavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older

03.02.25GlobeNewswireBavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025

31.01.25GlobeNewswireBavarian Nordic – Completion of Share Buy-Back Program

31.01.25GlobeNewswireBavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

27.01.25GlobeNewswireBavarian Nordic – Transactions in Connection with Share Buy-Back Program

20.01.25GlobeNewswireBavarian Nordic – Transactions in Connection with Share Buy-Back Program

09.01.25GlobeNewswireBavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million

16.12.24GlobeNewswireBavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India

13.12.24GlobeNewswireReport of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

13.12.24GlobeNewswireNew Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic

11.12.24GlobeNewswireBavarian Nordic to Launch DKK 150 Million Share Buy-back Program

29.11.24GlobeNewswireReport of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

29.11.24GlobeNewswireCapital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

15.11.24GlobeNewswireBavarian Nordic Announces Interim Results for the First Nine Months of 2024

29.10.24GlobeNewswireFirst Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine

26.09.24GlobeNewswireBavarian Nordic Upgrades its Financial Guidance for 2024

26.09.24GlobeNewswireBavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines

24.09.24GlobeNewswireBavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines

19.09.24GlobeNewswireBavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents

18.09.24GlobeNewswireGavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa

13.09.24GlobeNewswireBavarian Nordic Receives WHO Prequalification for Mpox Vaccine

12.09.24GlobeNewswireBavarian Nordic Provides Update on the Mpox Vaccine Supply Situation

06.09.24GlobeNewswireReport of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

05.09.24GlobeNewswireReport of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

05.09.24GlobeNewswireFirst Doses of Bavarian Nordic’s Mpox Vaccine Now Arriving in the Democratic Republic of Congo

05.09.24GlobeNewswireCapital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

Bavarian Nordic News

Bavarian Nordic News: auf dieser Seite finden Sie alle Bavarian Nordic News und Nachrichten zur Bavarian Nordic Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Bavarian Nordic News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Bavarian Nordic News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.